Trial Profile
A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Parallel-Arm, Multicenter Study to Evaluate the Efficacy and Safety of CAT-354, a Recombinant Human Monoclonal Antibody Directed Against Interleukin-13 (IL-13), on Asthma Control in Adults With Uncontrolled, Moderate-to-severe, Persistent Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Dec 2021
Price :
$35
*
At a glance
- Drugs Tralokinumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors MedImmune
- 18 Dec 2021 This trial has been completed in Bulgaria, according to European Clinical Trials Database record. (3 Aug 2010)
- 30 Jul 2017 Results of PK/PD model pooled data from two phase II studies published in the Clinical Pharmacology and Therapeutics
- 27 Jun 2012 Results published in the European Respiratory Journal.